[Proliferating cell nuclear antigen/cyclin (PCNA/Cyclin) in thyroid carcinoma]

Area of Science:

• Oncology
• Immunohistochemistry
• Cell Biology

Context:

• Thyroid carcinoma diagnosis and prognosis remain challenging.
• Immunohistochemistry offers potential for improved diagnostic accuracy.
• Proliferating cell nuclear antigen (PCNA) is a marker of cell proliferation.

Purpose:

• To evaluate the utility of PC10 monoclonal antibody against PCNA/Cyclin for thyroid carcinoma typing.
• To assess the correlation between PCNA index and different types of thyroid carcinoma.
• To determine if PCNA detection can aid in predicting thyroid carcinoma prognosis.

Summary:

• An immunohistochemical study utilized PC10 antibody to measure PCNA/Cyclin expression in four thyroid carcinoma types.
• Significant statistical differences (P < 0.01) in PCNA index were observed between all carcinoma types.
• Papillary, follicular, medullary, and undifferentiated carcinomas showed distinct PCNA indices (35.36±9.59, 184.60±7.08, 392.43±31.66, 488.28±19.93, respectively).

Impact:

• PCNA/Cyclin detection is a reliable method for assessing proliferating cells in thyroid carcinoma.
• This technique can potentially be used to determine the prognosis of thyroid carcinoma.
• Establishes PCNA as a valuable biomarker for thyroid cancer classification and outcome prediction.